Immune-Related Adverse Events Can Predict Progression-Free and Overall Survival In Patients With Metastatic Renal Cell Carcinoma Treated With Immune Checkpoint Inhibitors

被引:1
|
作者
Silberg, Matteo [2 ]
Krabbe, Laura-Maria [3 ]
Boegemann, Martin [1 ]
Schrader, Andres Jan [1 ]
Tully, Karl [2 ]
Schlack, Katrin [1 ]
机构
[1] Univ Hosp Muenster, Dept Urol, Munster, Germany
[2] Ruhr Univ Bochum, Univ Hosp, Marien Hosp Herne, Dept Urol, Hoelkeskampring 40, D-44625 Herne, Germany
[3] Vivantes Network Hlth, Dept Urol, Berlin, Germany
关键词
CRITERIA;
D O I
10.1016/j.clgc.2024.102164
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Different combination therapies using anti - PD-1 / PD-L1 or CTLA-4 immune checkpoint inhibition (ICI) are widely used in patients with metastatic renal cell carcinoma (mRCC). In the absents of established biomarkers, immune-related adverse events (irAEs) have been discussed as potential predictors of response. Methods In this retrospective cohort study, data of 134 patients with mRCC undergoing ICI treatment (Nivolumab, Ipilimumab and Nivolumab, Pembrolizumab and Axitinib or Avelumab and Axitinib) between 2015 and 2021 were analyzed. To examine the utility of irAEs as predictors of overall survival (OS) and progression-free survival (PFS), separate Kaplan-Meier analyses and Cox proportional regression analyses were applied. Landmark analysis was conducted after 12 weeks to reduce immortal time bias. Result irAEs were observed in 85 patients (63.4%). Cutaneous (n = 52, 38.8%), endocrine (n = 33, 24.6%) and hepatic (n = 19, 14.2%) irAEs were most commonly observed. In Kaplan-Meier analysis, patients experiencing irAEs showed favorable median PFS (15 months, 95% CI, 9.91-20.09) compared to the non-irAE group (5 months, 95% CI, 3.56-6.44, P < .001). The median OS was 25 months (95% CI, 16.79-33.21) in the non-irAE group, while it was not reached in the irAE group (P = .002). In multivariable analysis, the presence of any irAE was associated with favorable PFS (HR 0.46 [95% CI, 0.26-0.82] P = .008) and OS (HR: 0.28 [95% CI, 0.12-0.63] P = .002), respectively. Landmark analysis after 12 weeks showed mixed results depending on the classification of the irAE group at the landmark time. Conclusion The presence of irAEs under ICI therapy in patients with mRCC is associated with better PFS and OS. Thus, manageable irAEs should not be cause for premature discontinuation of ICI therapy, as they seem to indicate favorable outcomes. Considering the time-dependent nature of irAEs is crucial estimating their value as predictive markers.
引用
收藏
页数:14
相关论文
共 50 条
  • [21] Impact of immune-related adverse events on survival in patients with metastastic urothelial carcinoma treated with immune-checkpoint inhibitors.
    Morales-Barrera, Rafael
    Suarez Rodriguez, Cristina
    Gonzalez, Macarena
    Ros, Javier
    Eugenia Semidey, Maria
    Hernandez, Ester Serra
    Mateo, Joaquin
    Saez, Carlos Fernandez
    Lozano, Fernando
    Mast, Richard
    Roche, Sarai
    Quintana, Angela
    Gutierrez Fernandez, Sara
    Serrano, Cesar
    Valverde, Claudia
    de Torres, Ines
    Maldonado, Xavier
    Morote, Juan
    Carles, Joan
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [22] A genomics model to predict immune-related adverse events in cancer patients treated with checkpoint inhibitors
    Scott, Emma C.
    Kazandjian, Dickran
    Santana-Quintero, Luis
    Ghazanchyan, Tigran
    Petrovskaya, Svetlana
    Zhang, Yong
    Rosenberg, Amy
    Rao, V. Ashutosh
    Marte, Jennifer L.
    Blumenthal, Gideon M.
    Theoret, Marc R.
    Pazdur, Richard
    Gulley, James L.
    Beaver, Julia A.
    CANCER RESEARCH, 2019, 79 (13)
  • [23] IMMUNE-RELATED ADVERSE EVENTS FOLLOWING IMMUNE CHECKPOINT INHIBITORS IN PATIENTS WITH HEPATOCELLULAR CARCINOMA
    Zhu, Kaiwen
    Niu, Chengu
    Liu, Hongli
    Okolo, Patrick
    GASTROENTEROLOGY, 2023, 164 (06) : S1431 - S1432
  • [24] Histologic subtype of cutaneous immune-related adverse events predicts overall survival in patients receiving immune checkpoint inhibitors
    Hirotsu, Kelsey E.
    Scott, Madeleine K. D.
    Marquez, Cesar
    Tran, Anhthy T.
    Rieger, Kerri E.
    Novoa, Roberto A.
    Robinson, William H.
    Kwong, Bernice Y.
    Zaba, Lisa C.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : 651 - 653
  • [25] Correlation Between Immune-Related Adverse Events and Prognosis in Hepatocellular Carcinoma Patients Treated With Immune Checkpoint Inhibitors
    Xu, Shuo
    Lai, Ruixue
    Zhao, Qian
    Zhao, Pandong
    Zhao, Ruili
    Guo, Zhanjun
    FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [26] Safety and efficacy of restarting immune checkpoint inhibitors after clinically significant immune-related adverse events in metastatic renal cell carcinoma
    Abou Alaiwi, Sarah
    Xie, Wanling
    Nassar, Amin H.
    Dudani, Shaan
    Martini, Dylan
    Bakouny, Ziad
    Steinharter, John A.
    Nuzzo, Pier Vitale
    Flippot, Ronan
    Martinez-Chanza, Nieves
    Wei, Xiao
    McGregor, Bradley A.
    Kaymakcalan, Marina D.
    Heng, Daniel Y. C.
    Bilen, Mehmet A.
    Choueiri, Toni K.
    Harshman, Lauren C.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (01)
  • [27] ASSOCIATION OF IMMUNE-RELATED ADVERSE EVENTS WITH PROGNOSIS IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA TREATED WITH NIVOLUMAB
    Ishihara, Hiroki
    Takagi, Toshio
    Kondo, Tsunenori
    Homma, Chie
    Tachibana, Hidekazu
    Fukuda, Hironori
    Yoshida, Kazuhiko
    Iizuka, Junpei
    Kobayashi, Hirohito
    Okumi, Masayoshi
    Ishida, Hideki
    Tanabe, Kazunari
    JOURNAL OF UROLOGY, 2019, 201 (04): : E71 - E71
  • [28] Predictors of Response, Progression-Free Survival, and Overall Survival in Patients With Lung Cancer Treated With Immune Checkpoint Inhibitors
    Memmott, Regan M.
    Wolfe, Adam R.
    Carbone, David P.
    Williams, Terence M.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (07) : 1086 - 1098
  • [29] C-reactive protein and immune-related adverse events as prognostic biomarkers in immune checkpoint inhibitor treated metastatic renal cell carcinoma patients
    Kankkunen, Elisa
    Penttila, Patrick
    Peltola, Katriina
    Bono, Petri
    ACTA ONCOLOGICA, 2022, 61 (10) : 1240 - 1247
  • [30] Analysis of immune-related adverse events in gastrointestinal malignancy patients treated with immune checkpoint inhibitors
    Niu, Chengu
    Zhu, Kaiwen
    Zhang, Jing
    Joshi, Utsav
    Liu, Hongli
    Zahid, Salman
    Jadhav, Nagesh
    Okolo, Patrick I.
    INTERNATIONAL JOURNAL OF CANCER, 2024, 154 (07) : 1261 - 1271